Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3

被引：0
|
作者：
Penel, Nicolas [1 ]
机构：
[1] Ctr Oscar Lambret, Dept Cancerol Gen, 3 Rue F Combemale, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷 / 09期
关键词：
Renal cell carcinoma; Adjuvant; Pazopanib; NEPHRECTOMY;
D O I：
10.1016/j.bulcan.2017.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [1] Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
    Zhou, Qingbo
    Liu, Jianjiang
    Xie, Shaoqin
    MEDICINE, 2024, 103 (22) : E38329
  • [2] Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May, Sabine
    May, Matthias
    Gilfrich, Christian
    Wieland, Wolf Ferdinand
    Burger, Maximilian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 813 - 823
  • [3] Combining Checkpoint and Tyrosine Kinase Inhibitor in the Treatment of Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (05) : 247 - 247
  • [4] MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA
    Jambunathan, Bhaghyasree
    Dergham, Abdo
    Bhattacharjee, Sayani
    Wynn, Rebecca
    Sindhwani, Puneet
    Petros, Firas
    Nadiminty, Nagalakshmi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E702 - E702
  • [5] Pazopanib The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
    Keisner, Sidney V.
    Shah, Sachin R.
    DRUGS, 2011, 71 (04) : 443 - 454
  • [6] Pazopanib: The newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
    Keisner S.V.
    Shah S.R.
    Drugs, 2011, 71 (4) : 443 - 454
  • [7] RETROSPECTIVE REVIEW OF ADJUVANT TREATMENT OF ADVANCED RENAL CELL CARCINOMA WITH ORAL TYROSINE KINASE INHIBITORS
    Frost, J.
    Hamilton, R. D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 336 - 336
  • [8] First randomized phase 3 study on adjuvant therapy with a tyrosine kinase inhibitor in high-risk renal cell carcinoma
    Gruellich, Carsten
    ONKOLOGE, 2016, 22 (11): : 886 - 887
  • [9] Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
    Hailiang Zhang
    Lin Bai
    Xin-Qiang Wu
    Xi Tian
    Jinwen Feng
    Xiaohui Wu
    Guo-Hai Shi
    Xiaoru Pei
    Jiacheng Lyu
    Guojian Yang
    Yang Liu
    Wenhao Xu
    Aihetaimujiang Anwaier
    Yu Zhu
    Da-Long Cao
    Fujiang Xu
    Yue Wang
    Hua-Lei Gan
    Meng-Hong Sun
    Jian-Yuan Zhao
    Yuanyuan Qu
    Dingwei Ye
    Chen Ding
    Nature Communications, 14
  • [10] Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
    Zhang, Hailiang
    Bai, Lin
    Wu, Xin-Qiang
    Tian, Xi
    Feng, Jinwen
    Wu, Xiaohui
    Shi, Guo-Hai
    Pei, Xiaoru
    Lyu, Jiacheng
    Yang, Guojian
    Liu, Yang
    Xu, Wenhao
    Anwaier, Aihetaimujiang
    Zhu, Yu
    Cao, Da-Long
    Xu, Fujiang
    Wang, Yue
    Gan, Hua-Lei
    Sun, Meng-Hong
    Zhao, Jian-Yuan
    Qu, Yuanyuan
    Ye, Dingwei
    Ding, Chen
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345